Jan 2, 2025, 16:41
Ahmed Kotb: Triplet Regimens in AML – Promises and Challenges
Ahmed Kotb, Hematologist and Bone marrow transplanter at King Faisal Specialist Hospital International Holding Company (KFSHI), shared a post on LinkedIn:
“Triplet Regimens in AML: Promises & Challenges.
IDH1/2-Mutated AML:
HMA+VEN+IDHi → 92% CRc, 2-year OS 82%
Low early mortality (30d: 0%, 60d: 2%)
FLT3-Mutated AML:
HMA+VEN+FLT3i →93% CRc, 82% MRD-ve, 41% SCT
Challenges:
Risk of myelosuppression & toxicity.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 2, 2025, 16:41
Jan 2, 2025, 16:34
Jan 2, 2025, 16:31
Jan 2, 2025, 16:09
Jan 2, 2025, 16:05
Jan 2, 2025, 16:02